Astellas Pharma (ALPMY) and Sangamo (SGMO) announced they have entered into a license agreement allowing Astellas to leverage ...

Astellas Pharma and Sangamo Therapeutics have signed a licence agreement for a neurotropic adeno-associated virus (AAV) ...

This manuscript provides valuable information about the genesis of CPSF6 condensates due to HIV-1 infection. However, the evidence is incomplete as it is missing more functional assays. Furthermore, ...

The agreement grants the Japanese pharma the worldwide license to initially use Sangamo's proprietary neurotropic ...

A team of researchers led by Susan Hafenstein, PhD, Professor and CryoEM Director at The Hormel Institute, University of ...

Astellas Pharma partners with Sangamo Therapeutics to license STAC-BBB, a neurotropic AAV capsid for neurological disease ...

Assembly Biosciences (ASMB) announced interim safety, pharmacokinetic, PK, and efficacy results from participants with chronic hepatitis B ...

Assembly Biosciences, Inc. (ASMB), a biotechnology company, Thursday announced encouraging interim data from Phase 1b study of ...

Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced they have entered into a ...